MODEL VERDICT
Revolution Medicines, Inc. (RVMD) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Jan 11, 2026 | NEUTRAL | 0.17 | $118.64 | CURRENT | -18.5% |
| Dec 12, 2025 | NEUTRAL | 0.18 | $78.92 | Below threshold | +22.6% |
| Nov 12, 2025 | NEUTRAL | 0.18 | $65.83 | Below threshold | +46.9% |
| Oct 13, 2025 | NEUTRAL | 0.20 | $48.75 | Below threshold | +143.4% |
| Sep 13, 2025 | NEUTRAL | 0.20 | $46.55 | Below threshold | +69.5% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 4.69 | 3.41 | 1.85 | 9.70 | 2.92 |
| P/B Ratio | 4.28 | 3.14 | 1.78 | 9.28 | 2.75 |
| P/S Ratio | 114.55 | 61.85 | 54.28 | 280.24 | 110.51 |
Insufficient data to determine relative valuation for RVMD.
Fair value could not be computed for RVMD due to insufficient comparable data.
RVMD's current P/E of -17.1x compares to the industry median of 21.4x (48 peers in the group). This represents a -180.0% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
20 analysts cover RVMD with a consensus rating of Buy. The consensus price target is $122.25 (range: $73.00 — $170.00), implying +19.8% upside from the current price. Grade breakdown: Strong Buy (1), Buy (18), Hold (1), Sell (0), Strong Sell (0).
The model confidence score is 49/100, based on: data completeness (0), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for RVMD.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.